Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.
Di Biase L, Lakkireddy DJ, Marazzato J, Velasco A, Diaz JC, Navara R, Chrispin J, Rajagopalan B, Natale A, Mohanty S, Zhang X, Della Rocca D, Dalal A, Park K, Wiley J, Batchelor W, Cheung JW, Dangas G, Mehran R, Romero J; ACC Electrophysiology and Interventional Councils.
J Am Coll Cardiol. 2024 Jan 2;83(1):82-108. doi: 10.1016/j.jacc.2023.09.831.
Air Embolism after Percutaneous Lung Biopsy or Ablation: A Report of Six Cases.
Choi R, Phan HK, Gurusamy V, Sheth RA, Odisio BC, Hong K, Tam AL.
Radiol Imaging Cancer. 2025 May;7(3):e240379. doi: 10.1148/rycan.240379.
Surgical ablation supplemented by ethanol injection for ventricular tachycardia refractory to percutaneous ablation.
Yang G, Shao Y, Gu W, Ni B, Yang B, Zhang F, Ju W, Chen H, Gu K, Li M, Chen Y, Sun H, Tam TK, Wu Y, Chen M.
J Cardiovasc Electrophysiol. 2021 Sep;32(9):2462-2470. doi: 10.1111/jce.15162. Epub 2021 Jul 21.
Complications and Anticoagulation Strategies for Percutaneous Epicardial Ablation Procedures.
Nakamura T, Davogustto GE, Schaeffer B, Tanigawa S, Muthalaly RG, Kanagasundram A, John RM, Michaud GF, Tedrow UB, Stevenson WG.
Circ Arrhythm Electrophysiol. 2018 Nov;11(11):e006714. doi: 10.1161/CIRCEP.118.006714.
Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation.
Madsen LH, Lund T, Grieg Z, Nygaard S, Holmvang L, Jurlander B, Grande P, Christensen G, Atar D.
Cardiology. 2009;114(3):167-73. doi: 10.1159/000226596. Epub 2009 Jul 2.
Long-term electrocardiographic findings in patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation.
Haghjoo M.
J Electrocardiol. 2007 Oct;40(4):357.e1-2. doi: 10.1016/j.jelectrocard.2007.04.005.
Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.
Savelieva I, Camm AJ.
Clin Cardiol. 2014 Jan;37(1):32-47. doi: 10.1002/clc.22204. Epub 2013 Nov 19.
Vector electrocardiographic alterations after percutaneous septal ablation in obstructive hypertrophic cardiomyopathy. Possible anatomic causes.
Riera AR, de Cano SJ, Cano MN, Gimenez VM, de Padua Fleury Neto LA, Sousa JE.
Arq Bras Cardiol. 2002 Nov;79(5):466-75. doi: 10.1590/s0066-782x2002001400004.
Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
Guo H, Wang P, Xing Y, Peng F, Jiang J, Yang B, You B, Qiu Y, Lee JD.
J Electrocardiol. 2007 Oct;40(4):356.e1-6. doi: 10.1016/j.jelectrocard.2006.12.003. Epub 2007 Feb 20.
Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy.
Li CY, Shi YQ.
Arq Bras Cardiol. 2019 Apr;112(4):432-438. doi: 10.5935/abc.20190060. Epub 2019 Apr 1.
